{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:09:59Z","timestamp":1785931799790,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008986","name":"University of Guelph","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["843296"],"award-info":[{"award-number":["843296"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["946085"],"award-info":[{"award-number":["946085"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["499834"],"award-info":[{"award-number":["499834"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omto.2023.100748","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:31:32Z","timestamp":1699576292000},"page":"100748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Jessica A.","family":"Minott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"van Vloten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake G.E.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Santry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Matuszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Goens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Viloria-Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byram W.","family":"Bridle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-2406","authenticated-orcid":false,"given":"Sarah K.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2023.100748_bib1","series-title":"Key Statistics for Ovarian Cancer","author":"Society","year":"2022"},{"key":"10.1016\/j.omto.2023.100748_bib2","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omto.2023.100748_bib3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2023.100748_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.semcancer.2021.06.021","article-title":"Virus-inspired strategies for cancer therapy","volume":"86","author":"Ma","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omto.2023.100748_bib5","doi-asserted-by":"crossref","first-page":"e004167","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.100748_bib6","doi-asserted-by":"crossref","first-page":"e1442169","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omto.2023.100748_bib7","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","article-title":"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication","volume":"15","author":"Prestwich","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.100748_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/gt.2009.161","article-title":"Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma","volume":"17","author":"Galivo","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.omto.2023.100748_bib9","doi-asserted-by":"crossref","first-page":"e2013","DOI":"10.1002\/rmv.2013","article-title":"Orf virus: A promising new therapeutic agent","volume":"29","author":"Wang","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.omto.2023.100748_bib10","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1099\/vir.0.028894-0","article-title":"Characterization of immunostimulatory components of orf virus (parapoxvirus ovis)","volume":"92","author":"Friebe","year":"2011","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.omto.2023.100748_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0165-2427(99)00119-1","article-title":"Immunomodulation by virulence proteins of the parapoxvirus orf virus","volume":"72","author":"Haig","year":"1999","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.omto.2023.100748_bib12","first-page":"311","article-title":"Ovine diseases","volume":"29","author":"Haig","year":"1998","journal-title":"Orf. Vet. Res."},{"key":"10.1016\/j.omto.2023.100748_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/vaccines9111341","article-title":"Immunomodulatory Strategies for Parapoxvirus: Current Status and Future Approaches for the Development of Vaccines against Orf Virus Infection","volume":"9","author":"Bukar","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omto.2023.100748_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.omtm.2021.08.004","article-title":"Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy","volume":"23","author":"van Vloten","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2023.100748_bib15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/mt.2011.301","article-title":"ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic","volume":"20","author":"Rintoul","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2023.100748_bib16","doi-asserted-by":"crossref","first-page":"845259","DOI":"10.3389\/fmicb.2022.845259","article-title":"The Combined Use of Orf Virus and PAK4 Inhibitor Exerts Anti-tumor Effect in Breast Cancer","volume":"13","author":"Deng","year":"2022","journal-title":"Front Microbiol."},{"key":"10.1016\/j.omto.2023.100748_bib17","doi-asserted-by":"crossref","first-page":"e004335","DOI":"10.1136\/jitc-2021-004335","article-title":"Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer","volume":"10","author":"van Vloten","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.100748_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103(+)\/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2023.100748_bib19","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2010-06-287243","article-title":"Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFN{gamma}: role of CD18, ICAM-1, and ICAM-3","volume":"117","author":"Costantini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omto.2023.100748_bib20","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.18632\/oncotarget.2181","article-title":"Neutrophils with protumor potential could efficiently suppress tumor growth after cytokine priming and in presence of normal NK cells","volume":"5","author":"Sun","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omto.2023.100748_bib21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omto.2023.100748_bib22","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/0008-5472.CAN-10-3025","article-title":"IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells","volume":"71","author":"Boudreau","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.100748_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2023.100748_bib24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2023.100748_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1189\/jlb.0510250","article-title":"The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity","volume":"89","author":"Costantini","year":"2011","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omto.2023.100748_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omto.2023.100748_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omto.2023.100748_bib28","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1128\/JVI.78.17.9400-9411.2004","article-title":"Immunomodulatory effects of inactivated parapoxvirus ovis (ORF virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells","volume":"78","author":"Friebe","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2023.100748_bib29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/mt.2010.312","article-title":"Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer","volume":"19","author":"Li","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2023.100748_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.cgt.7700784","article-title":"Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12","volume":"12","author":"Parker","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2023.100748_bib31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/cells9020400","article-title":"Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omto.2023.100748_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.100748_bib33","doi-asserted-by":"crossref","first-page":"701067","DOI":"10.1155\/2015\/701067","article-title":"Distinct Functions of Neutrophil in Cancer and Its Regulation","volume":"2015","author":"Granot","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.omto.2023.100748_bib34","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2023.100748_bib35","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","article-title":"Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice","volume":"67","author":"Robinson-Smith","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.100748_bib36","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1158\/0008-5472.CAN-06-4410","article-title":"Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression","volume":"67","author":"Bak","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2023.100748_bib37","doi-asserted-by":"crossref","first-page":"e0155189","DOI":"10.1371\/journal.pone.0155189","article-title":"Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2023.100748_bib38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/01.qco.0000216622.75326.ef","article-title":"Orf virus infection and host immunity","volume":"19","author":"Haig","year":"2006","journal-title":"Curr. Opin. Infect Dis."},{"key":"10.1016\/j.omto.2023.100748_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/vaccines8020295","article-title":"Orf Virus-Based vaccine vector D1701-V induces strong CD8+ T Cell response against the transgene but not against ORFV-Derived epitopes","volume":"8","author":"Reguzova","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omto.2023.100748_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","article-title":"Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials","volume":"7","author":"LaRocca","year":"2018","journal-title":"Clin. Transl Med."},{"key":"10.1016\/j.omto.2023.100748_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1439-0450.2002.00539.x","article-title":"Parapoxviruses: from the lesion to the viral genome","volume":"49","author":"Buttner","year":"2002","journal-title":"J.\u00a0Vet. Med. B Infect Dis. Vet. Public Health"},{"key":"10.1016\/j.omto.2023.100748_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1535-7163.MCT-08-0864","article-title":"ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"8","author":"Greenaway","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omto.2023.100748_bib43","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1749-6632.1957.tb49710.x","article-title":"Interpretation of host response in quantitative studies on animal viruses","volume":"69","author":"Bryan","year":"1957","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.omto.2023.100748_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2043-9113-2-5","article-title":"Monte Carlo simulation of the Spearman-Kaerber TCID50","volume":"2","author":"Wulff","year":"2012","journal-title":"J.\u00a0Clin. Bioinforma"},{"key":"10.1016\/j.omto.2023.100748_bib45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.omtm.2019.01.012","article-title":"Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies","volume":"13","author":"van Vloten","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2023.100748_bib46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omtm.2019.06.010","article-title":"Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies","volume":"14","author":"van Vloten","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omto.2023.100748_bib47","doi-asserted-by":"crossref","first-page":"1038340","DOI":"10.3389\/fimmu.2022.1038340","article-title":"Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies","volume":"13","author":"Minott","year":"2022","journal-title":"Front Immunol."}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:26:09Z","timestamp":1762496769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770523000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":47,"alternative-id":["S2372770523000979"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2023.100748","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinetic analysis of oncolytic OrfV-induced innate and adaptive immune responses in a murine model of late-stage ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2023.100748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100748"}}